New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
06:55 EDTTPI, TPI, TPI, ANX, ANX, ANX, AGEN, AGEN, AGEN, CTSO, CTSO, CTSO, ATOS, ATOS, ATOS, SYN, SYN, SYN, OXBT, OXBT, OXBT, CLRX, CLRX, CLRX, BONE, BONE, BONEOneMedPlace to host a forum
6th Annual OneMedForum 2013 is being held in San Francisco on January 7-9.
News For TPI;ANX;AGEN;CTSO;ATOS;SYN;OXBT;CLRX;BONE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
08:08 EDTATOSAtossa Genetics receives CE Mark for ForeCYTE breast aspirator device
Atossa Genetics announced it has received certification to Annex II of the European Medical Device Directive from its European Notified Body, DQS Medizinprodukte GmbH, which allows Atossa to place the "CE" Mark on the ForeCYTE Breast Aspirator for distribution in the European Union and its member states. DQS Medizinprodukte GmbH, a Notified Body/Registrar, is also a participant in the FDA's third-party inspection program.
06:59 EDTSYNSynthetic Biologics granted patent for C. difficile
Synthetic Biologics has been issued a Notice of Allowance by the USPTO for a composition of matter patent application that covers the lead product in its C. difficile program, SYN-004. This is Synthetic Biologics' first allowed patent application directly pertaining to SYN-004 in the U.S. SYN-004 is Synthetic Biologics' novel oral enzyme drug candidate designed as the first and only prophylactic treatment intended to prevent the development of C. difficile infections.
October 21, 2014
14:13 EDTTPITianyin Pharmaceutical received notices of non-compliance from NYSE MKT
Subscribe for More Information
October 20, 2014
17:18 EDTSYNGreat Point Partners reports 9.98% passive stake in Synthetic Biologics
Subscribe for More Information
October 15, 2014
11:35 EDTTPITianyin Pharmaceutical delays filing of annual report on Form 10-K
Subscribe for More Information
09:15 EDTTPITianyin Pharmaceutical trading halted, pending news
Subscribe for More Information
October 14, 2014
07:36 EDTBONEBacterin reports preliminary Q3 revenue $8.4M-$8.5M, consensus $9.15M
Bacterin announced preliminary, unaudited revenue for Q3. The company is expecting total revenue for Q3 to be in the range of $8.4M-$8.5M, representing an increase of 6%-7% when compared to $7.9M reported in 3Q13.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use